Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Coombs

Showing results (171-180 of 175) with videos related to

Pageof 18
Sort By:
You have reached the last page of results.This site can display upto 175 results.
Blood|July 12, 2024
Risk prediction for clonal cytopenia: multicenter real-world evidenceZhuoer Xie, Rami Komrokji, Najla Al Ali, et al.
Lancet (London, England)|March 7, 2021
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 studyAnthony R Mato, Nirav N Shah, Wojciech Jurczak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 22, 2020
Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective StrategyAnthony R Mato, Lindsey E Roeker, Ryan Jacobs, et al.
Blood|July 23, 2021
COVID-19 in patients with CLL: improved survival outcomes and update on management strategiesLindsey E Roeker, Toby A Eyre, Meghan C Thompson, et al.
Nature Genetics|October 27, 2020
Cancer therapy shapes the fitness landscape of clonal hematopoiesisKelly L Bolton, Ryan N Ptashkin, Teng Gao, et al.
Pageof 18

Showing results (171-180 of 175) with videos related to

Sort By:
Pageof 18
You have reached the last page of results.This site can display upto 175 results.
Blood|July 12, 2024
Risk prediction for clonal cytopenia: multicenter real-world evidenceZhuoer Xie, Rami Komrokji, Najla Al Ali, et al.
Lancet (London, England)|March 7, 2021
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 studyAnthony R Mato, Nirav N Shah, Wojciech Jurczak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 22, 2020
Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective StrategyAnthony R Mato, Lindsey E Roeker, Ryan Jacobs, et al.
Blood|July 23, 2021
COVID-19 in patients with CLL: improved survival outcomes and update on management strategiesLindsey E Roeker, Toby A Eyre, Meghan C Thompson, et al.
Nature Genetics|October 27, 2020
Cancer therapy shapes the fitness landscape of clonal hematopoiesisKelly L Bolton, Ryan N Ptashkin, Teng Gao, et al.
Pageof 18